
#2836

Assessment of therapeutic antibody efficacy without the interference of murine Fc receptors allows for investigation of human antibody-dependent cellular cytotoxicity mediated by NK cells in the FcResolv[™] hIL-15 NOG mouse model



Background

Targeted antibody therapy is applied to treat various cancer types. In addition to the primary mode of action (MOA), which involves direct binding to the tumor antigen, indirect MOA acting through the constant region (Fc) of the antibody can enhance anti-tumor efficacy. Indirect mechanisms engage the innate immune system, mediated by both the complement system (complement-dependent cytotoxicity (CDC)) and immune cells (antibodydependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC)). These indirect mechanisms can complicate the evaluation and accurate assessment of antibody-induced ADCC by human NK cells in current mouse models. In immune-deficient mouse strains (e.g. NOG), false positives and/or negatives may occur due to interactions with murine Fc receptors. These can either result in anti-tumor responses via activation of the murine innate immune system or can interfere with the human-targeted therapy's primary MOA. To study the response to anti-cancer antibodies without the interference of these murine Fc receptor interactions and to investigate ADCC mediated by human NK cells, a novel mouse model deficient in Fc receptors and expressing human IL-15 (FcResolv[™] hIL-15 NOG) was employed for testing antibody therapies.



Methods

Patient-derived xenograft (PDX) tumor models were transplanted into hIL-15 NOG and FcResolv[™] hIL-15 NOG mice. A human head and neck squamous cell carcinoma and a lung adenocarcinoma PDX model were both treated with cetuximab. Treatment with pertuzumab and trastuzumab was applied in a breast ductal carcinoma PDX model. Based on growth kinetics, the lung cancer PDX model was chosen for further testing of ADCC in the NK cell-humanized FcResolv[™] hIL-15 NOG mouse.

PDX tumor transplantation	Antibody treatment		
			Evalution
			 treatment effication differences betw
cResolv [™] hIL-15 NOG PDX r	nice	a de martina de la companya de	differences betw
	liice		
		Antibodies te	ested
IL-15 NOG			ested nti-EGFR) for HN and
NL-15 NOG Patient-derived tumo	xenografts (PDX)	- Cetuximab (a	


Simone Rhein¹, Maria Stecklum¹, Monika Buczek², Janell Richardson², Jens Hoffmann¹

¹ EPO – Experimental Pharmacology & Oncology Berlin-Buch GmbH, Berlin, Germany ² Taconic Biosciences, Inc., Rensselaer, New York, United States

Results


Lung adenocarcinoma

Tumor fragments of Lu7462 were transplanted on FcResolv hIL-15 NOG and hIL-15 NOG mice and treated with cetuximab (50 mg/kg) or vehicle (n=10) at tumor volume (TV) of 0.1 cm³. Treatment was started on day 7 and applied i.v. for 5 days and than weekly for two weeks.




Head and neck squamous cell carcinoma


Tumor fragments of HN11587B were transplanted on FcResolv hIL-15 NOG and hIL-15 NOG mice and treated with cetuximab (50 mg/kg) or vehicle (n=10) at tumor volume (TV) of 0.1 cm³. Treatment was started on day 6 and applied i.v. biweekly for 10 weeks



Breast ductal carcinoma

Tumor fragments of Ma4898 were transplanted on FcResolv hlL-15 NOG and hlL-15 NOG mice and treatmen with trastuzumab (10 mg/ml), pertuzumab (30 mg/ml) or vehicle of established tumors with a at tumor volume (TV) of 0.1 cm³ was started on day 1 (n=10). Trastuzumab was applied i.v. biweekly for 6 weeks. Pertuzumab was continued with 15 mg/kg i.p weekly for 8 weeks.





On day 56, when most mice were still alive, an One-way ANOVA followed by Dunnett's multiple comparisons test was performed **showing for the pertuximab-treated groups a stati**stically significant difference in tumor volumes between mouse strains.

On day 70, Welch's t test, revealed again a statistically significant difference in tumor volumes of pertuximab-treated groups.

Significance code: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.001

ween mouse strains

Lu PDX


Contact: simone.rhein@epo-berlin.com; www.epo-berlin.com


CD56⁺ cells/ul blood

Day 50 to study end



B) Treatment of PDX tumor on NK cell-humanized FcResolvTM hIL-15 NOG mouse model





mice and no NK cell-dependent treatment effect observed in this tumor model.

A simple linear regression of the tumor volume curves of hIL-15 NOG cetuximab-treated groups were plotted from day 50 until study end. Tumor volume curves were analyzed with multiple unpaiered t test to evaluate potenital differences between curves. No difference in tumor volume curves between cetuximab-treated groups were detected independent FcResolv[™] hIL-15 NOG on NK cell-humanization. Vehicle-treated groups had to be terminated by day 26 (data not shown). Days after treatment star Plus NK cell — hIL-15 NOG + Cetuximab FcResolv hIL-15 NOG + Cetuximab

There was no difference in percent tumor growth inhibition between the FcResolv[™] hIL-15 NOG and hIL-15 NOG mice with regards to cetuximab treatment in the lung and head and neck cancer or for trastuzumab treatment of breast ductal carcinoma. However, pertuzumab treatment revealed a false positive efficacy, with the false positive effect more pronounced in hIL-15 NOG mice than in FcResolv[™] hIL-15 NOG mice. These results demonstrate that FcResolv[™] hIL-15 NOG mice serve as a suitable mouse model for a more accurate assessment of the therapeutic efficacy of anti-tumor antibodies. Additionally, evaluation of human-mediated ADCC of therapeutic antibodies in NK cell-humanized FcResolv™ hIL-15 NOG allows detection of effects specifically mediated by human NK cells.

